close

Fundraisings and IPOs

Date: 2011-11-07

Type of information: Grant

Company: Somantix (The Netherlands) VU University Medical Center Amsterdam (The Netherlands)

Investors: EuroTransBio (European Commission initiative to foster cross border research & development between companies and academia working in the biotech industry) (UE)

Amount: € 1.5 million

Funding type: grant

Planned used:

The subsidy is for a three year period and will allow design and development of small molecules for the inhibition of tumor angiogenesis in colon cancer.

Others:

* On November 7th 2011, a grant of € 1.5 million has been awarded to a multidisciplinary consortium including SomantiX and the VU University Medical Center Amsterdam by the European collaborative EuroTransBio (ETB) program. The subsidy is for a three year period and will allow design and development of small molecules for the inhibition of tumor angiogenesis in colon cancer. The project is a collaboration between the Dutch partners SomantiX BV and the Angiogenesis Laboratory of the Department of Medical Oncology at VU University Medical Center, and the German partners ElexoPharm GmbH, PharmBioTec GmbH and Saarland University.

Therapeutic area: Cancer - Oncology

Is general: Yes